Whyte, Michael P.
Article History
First Online: 19 February 2016
Competing interests
: M.P.W. has received consulting fees and research grant support from Enobia Pharma and honoraria, travel and research grant support from Alexion Pharmaceuticals, who have developed asfotase alfa to treat paediatric-onset hypophosphatasia as approved in Japan, Canada, the Europe Union and the USA.